
HIMS Stock Forecast & Price Target
HIMS Analyst Ratings
Bulls say
Hims & Hers Health Inc is experiencing significant growth, illustrated by a remarkable 70% year-over-year subscriber increase in Q4, bolstering its weight-loss segment and supporting expectations for sequential revenue growth. The company has diversified its offerings beyond the weight-loss category, including original specialties like sexual health, which lessens concentration risk compared to other direct-to-consumer platforms focused solely on weight-loss treatments. With strategic partnerships and advancements in drug development, Hims & Hers is well-positioned for sustained revenue growth, particularly as headwinds related to shipping diminish and as new specialties ramp up.
Bears say
Hims & Hers Health Inc. is experiencing a significant slowdown in revenue growth, as evidenced by disappointing earnings results for 4Q:25 and a weak revenue guidance for 1Q:26. The company's full-year 2026 revenue expectations have been lowered to $2.7 billion to $2.9 billion, which is notably below prior estimates, prompting a reassessment of its future financial performance and growth trajectory. Additionally, increasing legal and regulatory risks further contribute to the negative outlook for Hims & Hers, raising concerns about the sustainability of its business model in a challenging regulatory environment.
This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares